Allarity Therapeutics Files Amendment 5 to S-1 Registration Statement

TL;DR

<b>Allarity Therapeutics, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts related to securities offerings.</b>

AI Summary

Allarity Therapeutics, Inc. (ALLR) filed a Amended IPO Registration (S-1/A) with the SEC on April 17, 2024. Allarity Therapeutics, Inc. filed Amendment No. 5 to its Form S-1 Registration Statement. The filing is related to the Securities Act of 1933. The company's principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108. The company's phone number is (401) 426-4664. The filing was made on April 17, 2024.

Why It Matters

For investors and stakeholders tracking Allarity Therapeutics, Inc., this filing contains several important signals. This amendment suggests the company is actively working towards a public offering or other securities-related transactions, which could impact its capital structure and shareholder base. The S-1 filing is a crucial step for companies looking to raise capital through the sale of securities, and amendments often contain updated information or address SEC comments.

Risk Assessment

Risk Level: low — Allarity Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate significant new risks or positive developments.

Analyst Insight

Monitor future filings for details on the proposed securities offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 5 — Amendment Number (Amendment No. 5 to Form S-1)
• 1933 — Securities Act Year (Securities Act of 1933)
• 333-275224 — Registration Number (Registration No. 333-275224)
• 2024-04-17 — Filing Date (Filed as of date: 20240417)

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Registrant name
• 0001213900-24-033604 (other) — Accession Number
• 20240417 (date) — Filing date
• 333-275224 (other) — Registration Number
• 24 School St., 2nd Floor Boston, MA 02108 (location) — Business address
• (401) 426-4664 (phone) — Business phone
• Thomas H. Jensen (person) — Chief Executive Officer
• Venable LLP (company) — Legal counsel

FAQ

Industry Context

Allarity Therapeutics operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for specific details on the proposed offering.
2. Track subsequent amendments or effectiveness dates for the registration statement.
3. Analyze the company's financial health and business strategy in conjunction with this filing.

Key Dates

• 2024-04-17: Filing of Amendment No. 5 to Form S-1 — Indicates ongoing regulatory process for securities offering.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or responses to regulatory requirements rather than a completely new filing.

Key Financial Figures

• $2.00 — at an assumed public offering price of $2.00 per share, the last reported sale price
• $1.93 — rchase 36,933 shares of Common Stock at $1.93 per share, subject to adjustment upon c
• $2,500,000 — the stockholders' equity requirement of $2,500,000 will result in immediate delisting, sub
• $1.00 — of Common Stock has closed at less than $1.00 per share over the previous 30 consecut
• $4,900,000 — ly due and payable in the amount of USD $4,900,000 plus interest; ii the initiation, co

Filing Documents

• ea0203854-s1a5_allarity.htm (S-1/A) — 863KB
• img_001.jpg (GRAPHIC) — 9KB
• img_002.jpg (GRAPHIC) — 9KB
• 0001213900-24-033604.txt (&nbsp;) — 1145KB
• allr-20231231.xsd (EX-101.SCH) — 3KB
• allr-20231231_def.xml (EX-101.DEF) — 6KB
• allr-20231231_lab.xml (EX-101.LAB) — 9KB
• allr-20231231_pre.xml (EX-101.PRE) — 6KB
• ea0203854-s1a5_allarity_htm.xml (XML) — 2KB

USE OF PROCEEDS

USE OF PROCEEDS 14 CAPITALIZATION 15

DILUTION

DILUTION 17 MANAGEMENT 19

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 22 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 35

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL 38 DESCRIPTION OF OUR CAPITAL STOCK 39 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS 53

UNDERWRITING

UNDERWRITING 55 LEGAL MATTERS 62 EXPERTS 62 WHERE YOU CAN FIND ADDITIONAL INFORMATION 63 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 64 We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under " Where You Can Find More Information ." You should carefully read this prospectus as well as additional information described under " Incorporation of Certain Information by Reference ," before deciding to invest in our shares of Common Stock. Neither we nor the placement agent has authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the placement agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, the securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our securities. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. When used herein, unless the context requires otherwise, references to the "Company," "Allarity," "we," "our" and "us" refer to Allarity Therapeutics, Inc., a Delaware corporation. i SPE

View Full Filing

View this S-1/A filing on SEC EDGAR